(0.31%) 5 115.67 points
(0.31%) 38 357 points
(0.33%) 15 981 points
(-0.88%) $83.11
(5.77%) $2.03
(0.38%) $2 356.20
(0.48%) $27.67
(4.05%) $959.40
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 10.31%
Live Chart Being Loaded With Signals
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs...
Stats | |
---|---|
本日の出来高 | 0 |
平均出来高 | 0 |
時価総額 | 0 |
EPS | $0 ( 2024-02-28 ) |
次の収益日 | ( $-0.440 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0.109 (8.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Hall Christopher M | Buy | 400 000 | Stock Option (right to buy) |
2024-03-15 | Chen Richard | Buy | 175 000 | Stock Option (right to buy) |
2024-03-15 | Tachibana Aaron | Buy | 175 000 | Stock Option (right to buy) |
2024-03-15 | Moore Stephen Michael | Buy | 100 000 | Stock Option (right to buy) |
2024-03-01 | Myers Woodrow A Jr | Buy | 10 000 | Common Stock |
INSIDER POWER |
---|
-62.43 |
Last 98 transactions |
Buy: 3 908 824 | Sell: 9 802 248 |
ボリューム 相関
Personalis Inc 相関 - 通貨/商品
Personalis Inc 財務諸表
Annual | 2023 |
収益: | $73.48M |
総利益: | $18.21M (24.78 %) |
EPS: | $-2.25 |
FY | 2023 |
収益: | $73.48M |
総利益: | $18.21M (24.78 %) |
EPS: | $-2.25 |
FY | 2022 |
収益: | $65.05M |
総利益: | $13.35M (20.52 %) |
EPS: | $-2.48 |
FY | 2021 |
収益: | $85.49M |
総利益: | $31.66M (37.03 %) |
EPS: | $-1.490 |
Financial Reports:
No articles found.
Personalis Inc
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。